JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Establishment of a human ovarian clear cell carcinoma cell line mutant in PIK3CB but not PIK3CA

  • 0Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, Fukui, 910-1193, Japan.
Human Cell +

|

April 4, 2024

|

April 4, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

A new human ovarian clear cell carcinoma cell line, MTC-22, was established. This cell line exhibits rapid proliferation and key molecular features, making it valuable for ovarian cancer research.

Area Of Science

  • Oncology
  • Cell Biology
  • Genetics

Background

  • Ovarian clear cell carcinoma (OCCC) is a significant gynecologic malignancy.
  • Establishing robust cell lines is crucial for understanding OCCC pathophysiology and developing targeted therapies.

Purpose Of The Study

  • To establish and characterize a novel human ovarian clear cell carcinoma cell line (MTC-22).
  • To evaluate the potential of MTC-22 as a model for OCCC research, particularly for cases with specific genetic mutations.

Main Methods

  • Cell line establishment and continuous culture.
  • Morphological and ultrastructural analysis.
  • G-band karyotype analysis.
  • Immunohistochemical analysis for ovarian carcinoma-related molecules.
  • Mutation analysis of ARID1A and PIK3CB genes.

Main Results

  • MTC-22 cells demonstrated rapid proliferation (doubling time ~18 h) and monolayer growth without contact inhibition.
  • Ultrastructural examination revealed intracytoplasmic glycogen granules and well-developed mitochondria.
  • Karyotype analysis indicated a near-tetraploid complex karyotype.
  • MTC-22 cells expressed low-sulphated keratan sulphate, characteristic of non-mucinous and clear cell ovarian carcinomas.
  • The cell line retained key mutations found in the patient's tumor tissue, including in ARID1A and PIK3CB.

Conclusions

  • The MTC-22 cell line is a well-characterized model for ovarian clear cell carcinoma.
  • Its rapid growth and retention of specific mutations (ARID1A, PIK3CB) make it particularly useful for studying OCCC with these genetic alterations.
  • MTC-22 provides a valuable platform for developing and validating novel diagnostic and therapeutic strategies for ovarian clear cell carcinoma.

Keywords: